Cargando…

Outcome and Safety of Colistin Usage in Pediatric Cancer Patients with Carbapenem-Resistant Enterobacteriaceae Bacteremia at Children Cancer Hospital Egypt

BACKGROUND: Carbapenem resistant Enterobacteriacae (CRE) bloodstream infection (BSI) causes complicated infections, especially in immunocompromised patients. This study aimed to assess the renal toxicity and the efficacy of therapy with colistin in a cohort of pediatric cancer patients with BSIs due...

Descripción completa

Detalles Bibliográficos
Autores principales: Adel, Nagla, Khedr, Reham, Elanany, Mervat, Zaki, Hala F., Hafez, Hanafy, El-Abhar, Hanan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064897/
https://www.ncbi.nlm.nih.gov/pubmed/36695227
http://dx.doi.org/10.4103/aam.aam_209_21
_version_ 1785017991308509184
author Adel, Nagla
Khedr, Reham
Elanany, Mervat
Zaki, Hala F.
Hafez, Hanafy
El-Abhar, Hanan
author_facet Adel, Nagla
Khedr, Reham
Elanany, Mervat
Zaki, Hala F.
Hafez, Hanafy
El-Abhar, Hanan
author_sort Adel, Nagla
collection PubMed
description BACKGROUND: Carbapenem resistant Enterobacteriacae (CRE) bloodstream infection (BSI) causes complicated infections, especially in immunocompromised patients. This study aimed to assess the renal toxicity and the efficacy of therapy with colistin in a cohort of pediatric cancer patients with BSIs due to CRE and sensitivity to colistin. PATIENTS AND METHODS: This was an observational, prospective cohort study from May 2017 to October 2017 in Children's Cancer Hospital Egypt 57,357. All patients who had blood stream infections due to CRE receiving intravenous colistin were prospectively enrolled. We used a standardized case form to record patient characteristics, including age, sex, weight, underlying comorbidities, type of infection, causative organism, and antibiotic susceptibility testing. Daily doses, duration of colistin therapy, and co-administered antibiotics (aminoglycosides, vancomycin) were collected. Furthermore, clinical and microbiological responses to treatment were reported. The dosing schedule was based on a loading dose of 5 MU and a 5-MU twice-daily divided maintenance dose, titrated on renal function. Clinical cure, bacteriological clearance, and daily serum creatinine were recorded. RESULTS: One hundred and forty-one Blood Stream infectious episodes mainly due to Klebsiella Species (pneumoniae and Oxytoca) (27%) and Escherichia coli (68%) were analyzed. All strains were susceptible to colistin with Minimum inhibitory concentration (MICs) of 0.19–1.5 mg/L. Patients were predominantly females (69%), with a mean age of 7 years. It was used as a combination therapy with carbapenems (69.2%) or aminoglycosides (80%). The median duration of treatment was 9 days (Range 1–50 days). Clinical and microbiological cure was observed in 110 cases (80%). Acute kidney injury developed during five treatment courses (4%) in which colistin was used in combination with amikacin. No renal replacement therapy was required and subsided within 7 days from colistin discontinuation. CONCLUSIONS: Our study showed that colistin had a high efficacy without significant renal toxicity in severe infections due to CRE Gram-negative bacteria.
format Online
Article
Text
id pubmed-10064897
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-100648972023-04-01 Outcome and Safety of Colistin Usage in Pediatric Cancer Patients with Carbapenem-Resistant Enterobacteriaceae Bacteremia at Children Cancer Hospital Egypt Adel, Nagla Khedr, Reham Elanany, Mervat Zaki, Hala F. Hafez, Hanafy El-Abhar, Hanan Ann Afr Med Original Article BACKGROUND: Carbapenem resistant Enterobacteriacae (CRE) bloodstream infection (BSI) causes complicated infections, especially in immunocompromised patients. This study aimed to assess the renal toxicity and the efficacy of therapy with colistin in a cohort of pediatric cancer patients with BSIs due to CRE and sensitivity to colistin. PATIENTS AND METHODS: This was an observational, prospective cohort study from May 2017 to October 2017 in Children's Cancer Hospital Egypt 57,357. All patients who had blood stream infections due to CRE receiving intravenous colistin were prospectively enrolled. We used a standardized case form to record patient characteristics, including age, sex, weight, underlying comorbidities, type of infection, causative organism, and antibiotic susceptibility testing. Daily doses, duration of colistin therapy, and co-administered antibiotics (aminoglycosides, vancomycin) were collected. Furthermore, clinical and microbiological responses to treatment were reported. The dosing schedule was based on a loading dose of 5 MU and a 5-MU twice-daily divided maintenance dose, titrated on renal function. Clinical cure, bacteriological clearance, and daily serum creatinine were recorded. RESULTS: One hundred and forty-one Blood Stream infectious episodes mainly due to Klebsiella Species (pneumoniae and Oxytoca) (27%) and Escherichia coli (68%) were analyzed. All strains were susceptible to colistin with Minimum inhibitory concentration (MICs) of 0.19–1.5 mg/L. Patients were predominantly females (69%), with a mean age of 7 years. It was used as a combination therapy with carbapenems (69.2%) or aminoglycosides (80%). The median duration of treatment was 9 days (Range 1–50 days). Clinical and microbiological cure was observed in 110 cases (80%). Acute kidney injury developed during five treatment courses (4%) in which colistin was used in combination with amikacin. No renal replacement therapy was required and subsided within 7 days from colistin discontinuation. CONCLUSIONS: Our study showed that colistin had a high efficacy without significant renal toxicity in severe infections due to CRE Gram-negative bacteria. Wolters Kluwer - Medknow 2023 2023-01-24 /pmc/articles/PMC10064897/ /pubmed/36695227 http://dx.doi.org/10.4103/aam.aam_209_21 Text en Copyright: © 2023 Annals of African Medicine https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Adel, Nagla
Khedr, Reham
Elanany, Mervat
Zaki, Hala F.
Hafez, Hanafy
El-Abhar, Hanan
Outcome and Safety of Colistin Usage in Pediatric Cancer Patients with Carbapenem-Resistant Enterobacteriaceae Bacteremia at Children Cancer Hospital Egypt
title Outcome and Safety of Colistin Usage in Pediatric Cancer Patients with Carbapenem-Resistant Enterobacteriaceae Bacteremia at Children Cancer Hospital Egypt
title_full Outcome and Safety of Colistin Usage in Pediatric Cancer Patients with Carbapenem-Resistant Enterobacteriaceae Bacteremia at Children Cancer Hospital Egypt
title_fullStr Outcome and Safety of Colistin Usage in Pediatric Cancer Patients with Carbapenem-Resistant Enterobacteriaceae Bacteremia at Children Cancer Hospital Egypt
title_full_unstemmed Outcome and Safety of Colistin Usage in Pediatric Cancer Patients with Carbapenem-Resistant Enterobacteriaceae Bacteremia at Children Cancer Hospital Egypt
title_short Outcome and Safety of Colistin Usage in Pediatric Cancer Patients with Carbapenem-Resistant Enterobacteriaceae Bacteremia at Children Cancer Hospital Egypt
title_sort outcome and safety of colistin usage in pediatric cancer patients with carbapenem-resistant enterobacteriaceae bacteremia at children cancer hospital egypt
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064897/
https://www.ncbi.nlm.nih.gov/pubmed/36695227
http://dx.doi.org/10.4103/aam.aam_209_21
work_keys_str_mv AT adelnagla outcomeandsafetyofcolistinusageinpediatriccancerpatientswithcarbapenemresistantenterobacteriaceaebacteremiaatchildrencancerhospitalegypt
AT khedrreham outcomeandsafetyofcolistinusageinpediatriccancerpatientswithcarbapenemresistantenterobacteriaceaebacteremiaatchildrencancerhospitalegypt
AT elananymervat outcomeandsafetyofcolistinusageinpediatriccancerpatientswithcarbapenemresistantenterobacteriaceaebacteremiaatchildrencancerhospitalegypt
AT zakihalaf outcomeandsafetyofcolistinusageinpediatriccancerpatientswithcarbapenemresistantenterobacteriaceaebacteremiaatchildrencancerhospitalegypt
AT hafezhanafy outcomeandsafetyofcolistinusageinpediatriccancerpatientswithcarbapenemresistantenterobacteriaceaebacteremiaatchildrencancerhospitalegypt
AT elabharhanan outcomeandsafetyofcolistinusageinpediatriccancerpatientswithcarbapenemresistantenterobacteriaceaebacteremiaatchildrencancerhospitalegypt